Spotlight on Internal Medicine

Credits: 1.00 CME
Rethinking Migraine Treatment: New Therapies Impacting Patient Care
Stewart J. Tepper, MD
Forefront Collaborative

Rethinking Migraine Treatment: New Therapies Impacting Patient Care

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: July 15, 2019
Expires: July 14, 2020
60 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  2. Develop treatment plans in line with standards of practice for acute and preventive management of episodic and chronic migraine.
  3. Discuss unmet patient needs and burden of episodic and chronic migraine.
  4. Analyze safety and efficacy data for emerging therapies in acute and preventive treatment of migraine relative to current standards and clinically meaningful outcomes.

Activity Description

The thinking around both preventive and acute treatment of migraine is undergoing a radical change as new therapies emerge that target varied routes, some specific to known mechanisms of migraine pathophysiology. From new classes of treatment to emerging therapies and neuromodulatory devices, headache specialist and general neurologist, Stewart J. Tepper, MD, and Ana Felix, MD, FAAN, team up to provide a practical update for practicing clinicians on key treatment advances that are transforming migraine care.

Statement of Educational Need

With the recent approvals, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

The New Era of Migraine Treatment
Cases in Episodic and Chronic Migraine

Faculty

Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Ana Felix, MD, FAAN
Neurologist,
Assistant Professor,
Department of Internal Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Inc, Allergan, Alphasights, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Cefaly, Charleston Laboratories, Inc., DeepBench, Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, LLC, Magellan Rx Management, Neurolief Ltd., Nordic BioTech, Novartis, Pfizer, Scion Neurostim, LLC, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Inc., Dr. Reddy’s Laboratories, Ltd., electroCore, LLC, eNeura, Neurolief, Novartis, Scion Neurostim, LLC, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies, Inc.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva PharmaceuticalIndustries Ltd.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Faculty: Ana Felix, MD, FAAN
  • Planner (Forefront Collaborative):Krista Jaworski

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 80%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Krista_jaworski@forefrontcollab.com
812-340-4274

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: July 15, 2019
Expires: July 14, 2020
60 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  2. Develop treatment plans in line with standards of practice for acute and preventive management of episodic and chronic migraine.
  3. Discuss unmet patient needs and burden of episodic and chronic migraine.
  4. Analyze safety and efficacy data for emerging therapies in acute and preventive treatment of migraine relative to current standards and clinically meaningful outcomes.

Activity Description

The thinking around both preventive and acute treatment of migraine is undergoing a radical change as new therapies emerge that target varied routes, some specific to known mechanisms of migraine pathophysiology. From new classes of treatment to emerging therapies and neuromodulatory devices, headache specialist and general neurologist, Stewart J. Tepper, MD, and Ana Felix, MD, FAAN, team up to provide a practical update for practicing clinicians on key treatment advances that are transforming migraine care.

Statement of Educational Need

With the recent approvals, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

The New Era of Migraine Treatment
Cases in Episodic and Chronic Migraine

Faculty

Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Ana Felix, MD, FAAN
Neurologist,
Assistant Professor,
Department of Internal Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Inc, Allergan, Alphasights, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Cefaly, Charleston Laboratories, Inc., DeepBench, Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, LLC, Magellan Rx Management, Neurolief Ltd., Nordic BioTech, Novartis, Pfizer, Scion Neurostim, LLC, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Inc., Dr. Reddy’s Laboratories, Ltd., electroCore, LLC, eNeura, Neurolief, Novartis, Scion Neurostim, LLC, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies, Inc.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva PharmaceuticalIndustries Ltd.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Faculty: Ana Felix, MD, FAAN
  • Planner (Forefront Collaborative):Krista Jaworski

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 80%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Krista_jaworski@forefrontcollab.com
812-340-4274

Internal Medicine Presentations

1.00 CME / CNE
Medical Education Resources (MER)
Recognizing Progression in Autosomal Dominant Polycystic Kidney Disease: Focus on Primary Care

Recognizing Progression in Autosomal Dominant Polycystic Kidney Disease: Focus on Primary Care

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 CNE Contact Hour
Released: May 10, 2019
Expires: May 10, 2020
1.0 hour to complete

Accredited By

This activity is jointly provided by Medical Education Resources and CMEology.

Media

Internet activity

Target Audience

This certified activity is intended for primary care physicians and other health care providers who have the opportunity to care for patients with ADPKD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Formulate an appropriate and timely diagnosis of ADPKD, including risk of progression
  • Employ strategies to enhance multidisciplinary care across the continuum of ADPKD

Activity Description

This activity will feature a patient at high risk for progression of autosomal dominant polycystic kidney disease (ADPKD) and chronicle her journey through diagnosis, assessment, treatment planning, and monitoring. It will address the role of the primary care provider and will place emphasis on the primary care provider’s approach to initial testing and assessment, as well as recognizing indications for referral to a nephrologist. 

Statement of Educational Need

ADPKD is the most common genetic renal disorder. ADPKD is associated with a diminished quality of life and high health care utilization and costs. The unmet needs associated with ADPKD are among the greatest of all renal diseases. Recent advances in the diagnosis and treatment of ADPKD offer opportunities for timely intervention and better outcomes in patients. However, ADPKD is often identified late, and care may not be effectively coordinated with specialists. Even in those diagnosed with ADPKD in a timely manner, health care providers may not adequately identify patients at risk for rapid ADPKD progression, knowledge that is important to the individualization of management. Ongoing management for ADPKD requires multidisciplinary care and coordination to assess progression, optimize care for renal and nonrenal manifestations, and identify patients appropriate for disease-modifying therapy. This activity is intended to enhance knowledge in the diagnosis, assessment of progression risk, and referral considerations for primary care providers.

Goals (Purpose) of Program 

Health care providers who complete this activity should be able to recognize and assess the risk for disease progression in patients with ADPKD and provide and enhance ongoing management including monitoring and coordination of care.

Faculty

York Pei, MSc, MD, FRCPC
York Pei, MSc, MD, FRCPC
Professor of Medicine
University of Toronto
Staff Nephrologist
Toronto General Hospital
University Health Network
Toronto, Canada

Conflict of Interest Policy/Disclosure Statement

It is the policy of Medical Education Resources (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty has disclosed the following:

York Pei, MSc, MD, FRCPC
Consulting Fees: Otsuka, Sanofi, and Vertex

The following CMEology planners and managers, Beth Goodwin, Rob Lowney, and Dana Ravyn, PhD, MPH, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

The following MER planner and manager, Julie Johnson, PharmD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians and nurses.

Credit Designation
Medical Education Resources designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.  

Continuing Nursing Education

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 1.0 contact hour of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Instructions for Receiving Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Requirements for Successful Completion

Upon successfully completing the post-test with a score of 75% or better and the completion of the activity evaluation, the certificate will be made available immediately. 

Statement of Commercial Support

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

For questions about the certification of this activity, please contact CMEology at: info@cmeology.org.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 CNE Contact Hour
Released: May 10, 2019
Expires: May 10, 2020
1.0 hour to complete

Accredited By

This activity is jointly provided by Medical Education Resources and CMEology.

Media

Internet activity

Target Audience

This certified activity is intended for primary care physicians and other health care providers who have the opportunity to care for patients with ADPKD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Formulate an appropriate and timely diagnosis of ADPKD, including risk of progression
  • Employ strategies to enhance multidisciplinary care across the continuum of ADPKD

Activity Description

This activity will feature a patient at high risk for progression of autosomal dominant polycystic kidney disease (ADPKD) and chronicle her journey through diagnosis, assessment, treatment planning, and monitoring. It will address the role of the primary care provider and will place emphasis on the primary care provider’s approach to initial testing and assessment, as well as recognizing indications for referral to a nephrologist. 

Statement of Educational Need

ADPKD is the most common genetic renal disorder. ADPKD is associated with a diminished quality of life and high health care utilization and costs. The unmet needs associated with ADPKD are among the greatest of all renal diseases. Recent advances in the diagnosis and treatment of ADPKD offer opportunities for timely intervention and better outcomes in patients. However, ADPKD is often identified late, and care may not be effectively coordinated with specialists. Even in those diagnosed with ADPKD in a timely manner, health care providers may not adequately identify patients at risk for rapid ADPKD progression, knowledge that is important to the individualization of management. Ongoing management for ADPKD requires multidisciplinary care and coordination to assess progression, optimize care for renal and nonrenal manifestations, and identify patients appropriate for disease-modifying therapy. This activity is intended to enhance knowledge in the diagnosis, assessment of progression risk, and referral considerations for primary care providers.

Goals (Purpose) of Program 

Health care providers who complete this activity should be able to recognize and assess the risk for disease progression in patients with ADPKD and provide and enhance ongoing management including monitoring and coordination of care.

Faculty

York Pei, MSc, MD, FRCPC
York Pei, MSc, MD, FRCPC
Professor of Medicine
University of Toronto
Staff Nephrologist
Toronto General Hospital
University Health Network
Toronto, Canada

Conflict of Interest Policy/Disclosure Statement

It is the policy of Medical Education Resources (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty has disclosed the following:

York Pei, MSc, MD, FRCPC
Consulting Fees: Otsuka, Sanofi, and Vertex

The following CMEology planners and managers, Beth Goodwin, Rob Lowney, and Dana Ravyn, PhD, MPH, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

The following MER planner and manager, Julie Johnson, PharmD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity of any amount during the past 12 months.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians and nurses.

Credit Designation
Medical Education Resources designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.  

Continuing Nursing Education

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 1.0 contact hour of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Instructions for Receiving Credit

A brief post-test and course evaluation will follow the completion of the course. Please complete these questionnaires to claim credit for this course.

Requirements for Successful Completion

Upon successfully completing the post-test with a score of 75% or better and the completion of the activity evaluation, the certificate will be made available immediately. 

Statement of Commercial Support

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

For questions about the certification of this activity, please contact CMEology at: info@cmeology.org.

0.75 CME / CNE
Purdue University
The Advances in Monoclonal Antibody Therapeutics to Improve Outcomes in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

The Advances in Monoclonal Antibody Therapeutics to Improve Outcomes in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

Start

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit
0.75 CNE Contact Hour
Released: December 10, 2018
Expires: February 24, 2020
45 minutes to complete

Co-provided By

Target Audience

Rheumatologists, primary care physicians, internists, nurse practitioners, nurses, physician assistants, and other healthcare professionals involved in the management of patients with psoriatic arthritis and ankylosing spondylitis.

Learning Objectives

  1. Understand the immunopathology of PsA and AS, as well as early and accurate diagnosing, and disease monitoring
  2. Analyze clinical trial data of current and emerging therapeutic options for the management of PsA and AS
  3. Implement effective and safe treatment plans to improve outcomes in patients with PsA and AS

Activity Description

This CME/CNE activity is derived from content presented at the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) Annual Meeting in Dallas, Texas. The expert faculty, Dr. Alvin F. Wells, will review the characteristics of both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to ensure accurate detection and early diagnosis. Recent guidelines for the treatment and management of PsA and AS patients will be analyzed, along with approved and emerging therapeutic options and their clinical relevance. Dr. Wells will relay best practices for switching therapies and managing the adverse events associated with approved therapies utilizing the interprofessional team. At the conclusion of this activity, clinicians will become better acquainted with optimal treatment strategies to improve their care of psoriatic arthritis and ankylosing spondylitis patients.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with psoriatic arthritis and ankylosing spondylitis.

Agenda

  1. Psoriatic Arthritis and Ankylosing Spondylitis Update: Immunopathology, Accurate Diagnosing and Disease Monitoring
  2. Clinical Analysis of Current and Emerging Therapeutic Options for PsA and AS
  3. Implementing Safe and Effective Treatment Strategies to Improve Outcomes in Patients

Faculty

Alvin F. Wells, MD, PhD
Alvin F. Wells, MD, PhD
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Assistant Professor, Duke University Medical Center
Director, Rheumatology and Immunotherapy Center
Assistant Clinical Professor, Marquette University
Milwaukee, Wisconsin


Disclosures of Conflict of Interest

All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, reviewers, Purdue and AcademicCME staff have nothing to disclose.

Alvin F. Wells, MD, PhD

Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB. Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and AcademicCME, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This program has been approved for 0.75 contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity is supported by independent educational grants from Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME; Purdue University College of Pharmacy; Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit
0.75 CNE Contact Hour
Released: December 10, 2018
Expires: February 24, 2020
45 minutes to complete

Co-provided By

Target Audience

Rheumatologists, primary care physicians, internists, nurse practitioners, nurses, physician assistants, and other healthcare professionals involved in the management of patients with psoriatic arthritis and ankylosing spondylitis.

Learning Objectives

  1. Understand the immunopathology of PsA and AS, as well as early and accurate diagnosing, and disease monitoring
  2. Analyze clinical trial data of current and emerging therapeutic options for the management of PsA and AS
  3. Implement effective and safe treatment plans to improve outcomes in patients with PsA and AS

Activity Description

This CME/CNE activity is derived from content presented at the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) Annual Meeting in Dallas, Texas. The expert faculty, Dr. Alvin F. Wells, will review the characteristics of both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to ensure accurate detection and early diagnosis. Recent guidelines for the treatment and management of PsA and AS patients will be analyzed, along with approved and emerging therapeutic options and their clinical relevance. Dr. Wells will relay best practices for switching therapies and managing the adverse events associated with approved therapies utilizing the interprofessional team. At the conclusion of this activity, clinicians will become better acquainted with optimal treatment strategies to improve their care of psoriatic arthritis and ankylosing spondylitis patients.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with psoriatic arthritis and ankylosing spondylitis.

Agenda

  1. Psoriatic Arthritis and Ankylosing Spondylitis Update: Immunopathology, Accurate Diagnosing and Disease Monitoring
  2. Clinical Analysis of Current and Emerging Therapeutic Options for PsA and AS
  3. Implementing Safe and Effective Treatment Strategies to Improve Outcomes in Patients

Faculty

Alvin F. Wells, MD, PhD
Alvin F. Wells, MD, PhD
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Assistant Professor, Duke University Medical Center
Director, Rheumatology and Immunotherapy Center
Assistant Clinical Professor, Marquette University
Milwaukee, Wisconsin


Disclosures of Conflict of Interest

All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, reviewers, Purdue and AcademicCME staff have nothing to disclose.

Alvin F. Wells, MD, PhD

Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB. Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and AcademicCME, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This program has been approved for 0.75 contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity is supported by independent educational grants from Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME; Purdue University College of Pharmacy; Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

1.00 CME
Vindico
Chronic Idiopathic Urticaria: Improving Treatment, With a Focus on Patient Outcomes

Chronic Idiopathic Urticaria: Improving Treatment, With a Focus on Patient Outcomes

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: April 18, 2019
Expires: April 17, 2020
1 hour to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists and other health care professionals involved in the treatment of patients with chronic idiopathic urticaria (CIU).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work and activity.
  • Compare the strengths and limitations of current guideline approaches to the management of CIU.
  • Select treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Description

Urticaria, a common skin condition characterized by transient pruritic wheals, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration over 6 weeks may be diagnosed as having chronic idiopathic urticaria (CIU). CIU negatively impacts physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease awaiting bypass surgery. A US practice guideline issued in 2014 and an updated international guideline issued in 2018 are available to guide diagnosis and treatment of urticaria. Although the recommendations in these guidelines largely overlap, specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME activity will assess the impact of CIU on quality of life, particularly its impact on sleep, psychological functioning, work, and activity. Current guideline approaches to the management of CIU will be evaluated, as well as treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Chair

Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH

Disclosures
Royalty: CRC Press, Springer Publishing
Intellectual Property/Patent Details: University of Cincinnati
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire
Speakers Bureau: ALK, AstraZeneca, CSL Behring, Novartis, Optinose, Pharming, Sanofi, Shire
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire


Faculty

David A. Khan, MD
Professor of Medicine and Pediatrics
Allergy and Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX

Disclosures
Royalty: Elsevier, UpToDate
Speakers Bureau: Genentech
Data Safety Monitoring Committee: Aimmune


Prof. Dr. med. Dr. hc Torsten Zuberbier
Head of the Allergy Center Charité - Dermatology Clinic
Spokesman for the Comprehensive Allergy Center Charité
Allergy Center Charité
Charité - Universitätsmedizin Berlin
Berlin, Germany

Disclosures
Consulting Fee: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Speakers Bureau: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Committee Member: WHO-Initiative "Allergic Rhinitis and its Impact on Asthma" (ARIA)
Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI)
Head: European Centre for Allergy Research Foundation (ECARF)
Secretary General: Global Allergy and Asthma European Network (GA2LEN)
Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organisation (WAO)


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, April 18, 2019 to April 17, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Participation Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: April 18, 2019
Expires: April 17, 2020
1 hour to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists and other health care professionals involved in the treatment of patients with chronic idiopathic urticaria (CIU).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work and activity.
  • Compare the strengths and limitations of current guideline approaches to the management of CIU.
  • Select treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Description

Urticaria, a common skin condition characterized by transient pruritic wheals, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration over 6 weeks may be diagnosed as having chronic idiopathic urticaria (CIU). CIU negatively impacts physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease awaiting bypass surgery. A US practice guideline issued in 2014 and an updated international guideline issued in 2018 are available to guide diagnosis and treatment of urticaria. Although the recommendations in these guidelines largely overlap, specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME activity will assess the impact of CIU on quality of life, particularly its impact on sleep, psychological functioning, work, and activity. Current guideline approaches to the management of CIU will be evaluated, as well as treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Chair

Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH

Disclosures
Royalty: CRC Press, Springer Publishing
Intellectual Property/Patent Details: University of Cincinnati
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire
Speakers Bureau: ALK, AstraZeneca, CSL Behring, Novartis, Optinose, Pharming, Sanofi, Shire
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire


Faculty

David A. Khan, MD
Professor of Medicine and Pediatrics
Allergy and Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX

Disclosures
Royalty: Elsevier, UpToDate
Speakers Bureau: Genentech
Data Safety Monitoring Committee: Aimmune


Prof. Dr. med. Dr. hc Torsten Zuberbier
Head of the Allergy Center Charité - Dermatology Clinic
Spokesman for the Comprehensive Allergy Center Charité
Allergy Center Charité
Charité - Universitätsmedizin Berlin
Berlin, Germany

Disclosures
Consulting Fee: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Speakers Bureau: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Committee Member: WHO-Initiative "Allergic Rhinitis and its Impact on Asthma" (ARIA)
Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI)
Head: European Centre for Allergy Research Foundation (ECARF)
Secretary General: Global Allergy and Asthma European Network (GA2LEN)
Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organisation (WAO)


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, April 18, 2019 to April 17, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Participation Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

1.00 CME
Integrity Continuing Education, Inc.
Overcoming Barriers to Initiating or Intensifying Insulin Therapy: Best Practices for the Family Physician

Overcoming Barriers to Initiating or Intensifying Insulin Therapy: Best Practices for the Family Physician

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: April 11, 2019
Expires: April 11, 2020
1.0 hour to complete

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers (PCPs) involved in the management of patients with diabetes.

Activity Description

A BioDigital Human on-demand simulation activity has been developed as a derivative of the live program content. Simulation decisions and feedback will be supported by evidence-based content and expert faculty explanation.

Learning Objectives

Upon completion of this educational activity, participants will be able to:

  • Articulate clinical strategies for the timely initiation and modification, and intensification of insulin therapy to achieve glycemic control
  • Explain novel strategies to optimize insulin therapy in clinical practice to improve glucose control, reduce risk of weight gain and hypoglycemia, and increase patient access, acceptance and adherence
  • Utilize a patient-centered approach to individualize therapy and appropriately and effectively transition patients to insulin and insulin combinations

Statement of Educational Need

Although practitioners know poor glycemic control puts their patients at increased risk for developing diabetes complications, many delay insulin therapy. This program has been developed to aid family practice clinicians, who are at the frontline of care for these individuals. It will examine the safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data of newer basal insulin analogs as compared to older insulins. In addition, our faculty will review clinical data on combinations of basal insulin with rapid-acting insulin and GLP-1 receptor agonists and provide updates on newer follow-on insulin therapies. The ultimate goal is to provide clinicians with the skills to provide patient-centered care in order to individualize therapy and improve patient satisfaction, adherence and quality of life (QOL).

Faculty

Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Supervisor Nurse Practitioner
Henry Ford Health System
Division of Endocrinology, Diabetes and Bone Disorders
Detroit, Michigan


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Davida F. Kruger, MSN, APN-BC, BC-ADM
Advisory Boards: Abbott, Dexcom, Eli Lilly & Company, Intarcia, Janssen, Novo Nordisk, Sanofi Aventis,
Speakers Bureau: Abbott, AstraZeneca, BI Lilly, Dexcom, Insulet, Janssen, Lilly, Novo Nordisk, Valeritas,
Grants/Research Support Committees: Abbott, AstraZeneca, Dexcom, Eli Lilly, Hemsley Foundation, Lexicom, Novo Nordisk,
Stock: Dexcom

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 11, 2019 through April 11, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi US and Novo Nordisk do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by educational grants from Sanofi US and Novo Nordisk.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: April 11, 2019
Expires: April 11, 2020
1.0 hour to complete

Provided By

Target Audience

This educational initiative has been designed for family practice and primary care providers (PCPs) involved in the management of patients with diabetes.

Activity Description

A BioDigital Human on-demand simulation activity has been developed as a derivative of the live program content. Simulation decisions and feedback will be supported by evidence-based content and expert faculty explanation.

Learning Objectives

Upon completion of this educational activity, participants will be able to:

  • Articulate clinical strategies for the timely initiation and modification, and intensification of insulin therapy to achieve glycemic control
  • Explain novel strategies to optimize insulin therapy in clinical practice to improve glucose control, reduce risk of weight gain and hypoglycemia, and increase patient access, acceptance and adherence
  • Utilize a patient-centered approach to individualize therapy and appropriately and effectively transition patients to insulin and insulin combinations

Statement of Educational Need

Although practitioners know poor glycemic control puts their patients at increased risk for developing diabetes complications, many delay insulin therapy. This program has been developed to aid family practice clinicians, who are at the frontline of care for these individuals. It will examine the safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data of newer basal insulin analogs as compared to older insulins. In addition, our faculty will review clinical data on combinations of basal insulin with rapid-acting insulin and GLP-1 receptor agonists and provide updates on newer follow-on insulin therapies. The ultimate goal is to provide clinicians with the skills to provide patient-centered care in order to individualize therapy and improve patient satisfaction, adherence and quality of life (QOL).

Faculty

Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Supervisor Nurse Practitioner
Henry Ford Health System
Division of Endocrinology, Diabetes and Bone Disorders
Detroit, Michigan


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Davida F. Kruger, MSN, APN-BC, BC-ADM
Advisory Boards: Abbott, Dexcom, Eli Lilly & Company, Intarcia, Janssen, Novo Nordisk, Sanofi Aventis,
Speakers Bureau: Abbott, AstraZeneca, BI Lilly, Dexcom, Insulet, Janssen, Lilly, Novo Nordisk, Valeritas,
Grants/Research Support Committees: Abbott, AstraZeneca, Dexcom, Eli Lilly, Hemsley Foundation, Lexicom, Novo Nordisk,
Stock: Dexcom

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 11, 2019 through April 11, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi US and Novo Nordisk do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by educational grants from Sanofi US and Novo Nordisk.

1.25 CME / CNE
Vindico
Applying New Guidelines, Imaging, and Insights on Extending the Treatment Window in Acute Ischemic Stroke

Applying New Guidelines, Imaging, and Insights on Extending the Treatment Window in Acute Ischemic Stroke

Start

Activity Details

Free CME/CNE
1.25 AMA PRA Category 1 Credit(s)
1.25 contact hours
Released: April 5, 2019
Expires: April 4, 2020
1.25 hours to complete

Accredited By

This continuing education activity is provided by Vindico Medical Education.

Target Audience

The intended audience for this activity is neurologists, cardiologists, nurses, and other health care professionals involved in the treatment of patients with acute ischemic stroke.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Physicians

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Incorporate the use of image-guided treatment to improve outcomes in patients with AIS.

Nurses

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Assess the use of image-guided treatment to improve outcomes in patients with AIS.

Activity Description

Based on the success of several new clinical trials, the American Heart Association/American Stroke Association released updated stroke treatment guidelines in 2018. The guidelines address prehospital management, diagnosis, and treatment. Key revisions include extending the treatment window for mechanical thrombectomy in eligible patients and broadening the number of patients who qualify for thrombolysis. Advances in imaging techniques and technology have improved the overall management of acute ischemic stroke (AIS), and physicians must keep apprised of how to best incorporate these findings into practice to improve patient care. This CME/CNE activity will review the revised guidelines for patients with suspected AIS and patients who present outside the recommended time limit for thrombolysis, as well as the use of image-guided treatment to improve outcomes.

Faculty

Activity Chair

Philip B. Gorelick, MD, MPH
Adjunct Professor, Davee Department of Neurology
Division of Vascular Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures
No relevant financial relationships to disclose.


Faculty

Gregory W. Albers, MD
Director, Stanford Stroke Center
Coyote Foundation Professor of Neurology and
Neurological Sciences
Stanford University Medical Center
Stanford, CA
Disclosures
Consulting Fee: Genentech, iSchemaView, Medtronic
Ownership Interest: iSchemaView


Edward C. Jauch, MD, MS
Chief of System Research
Mission Research Institute/Mission Health
Asheville, NC
Disclosures
Consulting Fee: Biogen


Christopher A. Lewandowski, MD
Executive Vice Chair, Department of Emergency Medicine
Henry Ford Health System
Clinical Professor of Emergency Medicine, Wayne State University
Detroit, MI
Disclosures
Consulting Fee: Shire
Research Funding: NIH


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Maria Gannett, MSN, CRNP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center (ANCC) Commission on Accreditation’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide 1.25 contact hours for nurses.

This enduring material is approved for 1 year from the date of original release, April 5, 2019 to April 4, 2020.

Instructions for Receiving Credit

To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Learner-Paced Continuing Nursing Education Contact Hour Certificate.

MIPS Qualifying Activity

Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME/CNE Questions?
Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CNE
1.25 AMA PRA Category 1 Credit(s)
1.25 contact hours
Released: April 5, 2019
Expires: April 4, 2020
1.25 hours to complete

Accredited By

This continuing education activity is provided by Vindico Medical Education.

Target Audience

The intended audience for this activity is neurologists, cardiologists, nurses, and other health care professionals involved in the treatment of patients with acute ischemic stroke.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Physicians

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Incorporate the use of image-guided treatment to improve outcomes in patients with AIS.

Nurses

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Assess the use of image-guided treatment to improve outcomes in patients with AIS.

Activity Description

Based on the success of several new clinical trials, the American Heart Association/American Stroke Association released updated stroke treatment guidelines in 2018. The guidelines address prehospital management, diagnosis, and treatment. Key revisions include extending the treatment window for mechanical thrombectomy in eligible patients and broadening the number of patients who qualify for thrombolysis. Advances in imaging techniques and technology have improved the overall management of acute ischemic stroke (AIS), and physicians must keep apprised of how to best incorporate these findings into practice to improve patient care. This CME/CNE activity will review the revised guidelines for patients with suspected AIS and patients who present outside the recommended time limit for thrombolysis, as well as the use of image-guided treatment to improve outcomes.

Faculty

Activity Chair

Philip B. Gorelick, MD, MPH
Adjunct Professor, Davee Department of Neurology
Division of Vascular Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures
No relevant financial relationships to disclose.


Faculty

Gregory W. Albers, MD
Director, Stanford Stroke Center
Coyote Foundation Professor of Neurology and
Neurological Sciences
Stanford University Medical Center
Stanford, CA
Disclosures
Consulting Fee: Genentech, iSchemaView, Medtronic
Ownership Interest: iSchemaView


Edward C. Jauch, MD, MS
Chief of System Research
Mission Research Institute/Mission Health
Asheville, NC
Disclosures
Consulting Fee: Biogen


Christopher A. Lewandowski, MD
Executive Vice Chair, Department of Emergency Medicine
Henry Ford Health System
Clinical Professor of Emergency Medicine, Wayne State University
Detroit, MI
Disclosures
Consulting Fee: Shire
Research Funding: NIH


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Maria Gannett, MSN, CRNP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center (ANCC) Commission on Accreditation’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide 1.25 contact hours for nurses.

This enduring material is approved for 1 year from the date of original release, April 5, 2019 to April 4, 2020.

Instructions for Receiving Credit

To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Learner-Paced Continuing Nursing Education Contact Hour Certificate.

MIPS Qualifying Activity

Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME/CNE Questions?
Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CE
American Heart Association
AHA Enduring Webinar: Providing Healthcare Teams with Learning and Education to Impact Patient Care - Webinar I

AHA Enduring Webinar: Providing Healthcare Teams with Learning and Education to Impact Patient Care - Webinar I

Start

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: April 18, 2017
Expires: April 18, 2020
60 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and Nurses specific to treating patients with heart failure

Learning Objectives

At the completion of this course, the learner will be able to:

  • Educate healthcare professionals on evidence-based guidelines, especially newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.
  • Integrate patient-centered communication into their interactions with all patients with HF with reduced ejection fraction (HFrEF).
  • Evaluate new guidelines and data on therapies for HFrEF including their implications for patient selection and clinical practice.
  • Discuss the epidemiology, pathophysiology, and ongoing research of HFrEF.
  • Identify current best practices regarding diagnosis and treatment of HFrEF.
  • Summarize recent studies and latest evidence for current best practices in reducing preventable hospital readmissions in HF.
  • Describe the components of patient-centered communication.

Activity Description

This webinar focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. While addressing the epidemiology, pathophysiology, and ongoing research of HF with reduced ejection fraction, this webinar provides healthcare teams with learning and education to impact patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This multifaceted education initiative is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

10 minutes – Introduction
20 minutes – Implementing Recent Evidence-based Guidelines for the Pharmacological Management of Heart Failure
20 minutes – Strategies to Reduce Preventable Hospital Readmissions in HF
5 minutes – Closing remarks
5 minutes – Q & A

Presenters: Mark Drazner, MD, & Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA

Planning Committee

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern


Deborah Crabbe, MD – Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University


Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA – Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine


Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure


Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No Disclosures
Deborah Crabbe, MD – No Disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau

Accreditation Statements

ORIGINAL RELEASE DATE: 04/18/2017

TERMINATION DATE: 04/18/2020

LAST REVIEW DATE: April 2017

JOINT ACCREDITATION TERM: 04/18/2017 - 04/18/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hour. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  • Register and view the course online.
  • View the content in its entirety.
  • Complete a post-test with a minimum score of 75%.
  • Complete a survey of your learning experience.
  • Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis.

Disclaimer Statement

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Fred Porta
Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: April 18, 2017
Expires: April 18, 2020
60 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and Nurses specific to treating patients with heart failure

Learning Objectives

At the completion of this course, the learner will be able to:

  • Educate healthcare professionals on evidence-based guidelines, especially newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.
  • Integrate patient-centered communication into their interactions with all patients with HF with reduced ejection fraction (HFrEF).
  • Evaluate new guidelines and data on therapies for HFrEF including their implications for patient selection and clinical practice.
  • Discuss the epidemiology, pathophysiology, and ongoing research of HFrEF.
  • Identify current best practices regarding diagnosis and treatment of HFrEF.
  • Summarize recent studies and latest evidence for current best practices in reducing preventable hospital readmissions in HF.
  • Describe the components of patient-centered communication.

Activity Description

This webinar focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. While addressing the epidemiology, pathophysiology, and ongoing research of HF with reduced ejection fraction, this webinar provides healthcare teams with learning and education to impact patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This multifaceted education initiative is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

10 minutes – Introduction
20 minutes – Implementing Recent Evidence-based Guidelines for the Pharmacological Management of Heart Failure
20 minutes – Strategies to Reduce Preventable Hospital Readmissions in HF
5 minutes – Closing remarks
5 minutes – Q & A

Presenters: Mark Drazner, MD, & Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA

Planning Committee

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern


Deborah Crabbe, MD – Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University


Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA – Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine


Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure


Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No Disclosures
Deborah Crabbe, MD – No Disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau

Accreditation Statements

ORIGINAL RELEASE DATE: 04/18/2017

TERMINATION DATE: 04/18/2020

LAST REVIEW DATE: April 2017

JOINT ACCREDITATION TERM: 04/18/2017 - 04/18/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hour. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  • Register and view the course online.
  • View the content in its entirety.
  • Complete a post-test with a minimum score of 75%.
  • Complete a survey of your learning experience.
  • Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis.

Disclaimer Statement

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Fred Porta
Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CE
American Heart Association
AHA Enduring Webinar: Heart Failure Guidelines and Evidence-Based Practice Part II: Challenges and Opportunities

AHA Enduring Webinar: Heart Failure Guidelines and Evidence-Based Practice Part II: Challenges and Opportunities

Start

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: May 2, 2017
Expires: May 2, 2020
60 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and Nurses specific to treating patients with heart failure

Learning Objectives

At the completion of this course, the learner will be able to:

  • List different approaches to treatment of heart failure with reduced fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
  • Describe the different approaches to diagnosis and classification of heart failure.
  • List effective ways to ensure appropriate transition of care from the inpatient to outpatient setting.
  • Identify different diagnostic techniques and the various diagnosis options for heart failure patients and the importance of the correct diagnosis for follow-up treatment.
  • Apply strategies to improve the implementation of evidence-based heart failure guidelines and improved coordination of care amongst patient teams.
  • Discuss the updated guidelines surrounding newly FDA approved device options and their implications for the heart failure patient.

Activity Description

As an extension of the content covered in the first webinar, the second will address challenges, areas identified as greatest need from the first webinar and to reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This multifaceted education initiative is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

5 minutes – Introduction
10 minutes – Medication categories and Rationale for use
10 minutes – Transition care
10 minutes – Challenges in Self-Management of Heart Failure
10 minutes – Human connection
10 minutes – Case Studies
5 minutes – Q & A
5 minutes – Closing remarks

Presenters: Mark Drazner, MD, Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA, & Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA

Planning Committee

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern


Deborah Crabbe, MD – Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University


Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA – Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine


Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure


Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No Disclosures
Deborah Crabbe, MD – No Disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau

Accreditation Statements

ORIGINAL RELEASE DATE: 05/05/2017

TERMINATION DATE: 05/02/2020

LAST REVIEW DATE: April 2017

JOINT ACCREDITATION TERM: 05/02/2017 - 05/02/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hour. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  • Register and view the course online.
  • View the content in its entirety.
  • Complete a post-test with a minimum score of 80%.
  • Complete a survey of your learning experience.
  • Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis.

Disclaimer Statement

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Fred Porta
Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: May 2, 2017
Expires: May 2, 2020
60 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and Nurses specific to treating patients with heart failure

Learning Objectives

At the completion of this course, the learner will be able to:

  • List different approaches to treatment of heart failure with reduced fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
  • Describe the different approaches to diagnosis and classification of heart failure.
  • List effective ways to ensure appropriate transition of care from the inpatient to outpatient setting.
  • Identify different diagnostic techniques and the various diagnosis options for heart failure patients and the importance of the correct diagnosis for follow-up treatment.
  • Apply strategies to improve the implementation of evidence-based heart failure guidelines and improved coordination of care amongst patient teams.
  • Discuss the updated guidelines surrounding newly FDA approved device options and their implications for the heart failure patient.

Activity Description

As an extension of the content covered in the first webinar, the second will address challenges, areas identified as greatest need from the first webinar and to reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This multifaceted education initiative is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

5 minutes – Introduction
10 minutes – Medication categories and Rationale for use
10 minutes – Transition care
10 minutes – Challenges in Self-Management of Heart Failure
10 minutes – Human connection
10 minutes – Case Studies
5 minutes – Q & A
5 minutes – Closing remarks

Presenters: Mark Drazner, MD, Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA, & Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA

Planning Committee

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern


Deborah Crabbe, MD – Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University


Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA – Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine


Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure


Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No Disclosures
Deborah Crabbe, MD – No Disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN, FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau

Accreditation Statements

ORIGINAL RELEASE DATE: 05/05/2017

TERMINATION DATE: 05/02/2020

LAST REVIEW DATE: April 2017

JOINT ACCREDITATION TERM: 05/02/2017 - 05/02/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hour. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  • Register and view the course online.
  • View the content in its entirety.
  • Complete a post-test with a minimum score of 80%.
  • Complete a survey of your learning experience.
  • Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis.

Disclaimer Statement

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Fred Porta
Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 3

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 3

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
20 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Butler, 9:47 minutes: Expert discussion
Dr. Chow, 10:03 minutes: Expert discussion

Presenters

Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC
Co-Director of the Heart Institute
Chief of Division of Cardiology
Stony Brook University
Stony Brook, NY


Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology
Associate Professor
Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, CA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC – Amgen, Astra Zeneca, Bayer, Boelinger, Bristol Meyer Squib, Merck, Novartis: Consultant/Advisory board
Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology – Novartis: Consultant

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
20 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Butler, 9:47 minutes: Expert discussion
Dr. Chow, 10:03 minutes: Expert discussion

Presenters

Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC
Co-Director of the Heart Institute
Chief of Division of Cardiology
Stony Brook University
Stony Brook, NY


Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology
Associate Professor
Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, CA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC – Amgen, Astra Zeneca, Bayer, Boelinger, Bristol Meyer Squib, Merck, Novartis: Consultant/Advisory board
Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology – Novartis: Consultant

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 1

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 1

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
19 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Migliore, 9:47 minutes: Expert discussion
Dr. Martínez, 9:31 minutes: Expert discussion

Presenters

Ricardo Alberto Migliore, MD
Head of Diagnosis & Treatment, Cardiology Services
Hospital Interzonal de Agudos “Eva Perón”
San Martin, Buenos Aires, Argentina


Felipe Martínez, MD, FACC, FECS
Professor of Medicine
Cordoba National University
Director of Rusculleda Foundation
Cordoba, Argentina

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Ricardo Alberto Migliore, MD – No disclosures
Felipe Martínez, MD, FACC, FECS – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
19 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Migliore, 9:47 minutes: Expert discussion
Dr. Martínez, 9:31 minutes: Expert discussion

Presenters

Ricardo Alberto Migliore, MD
Head of Diagnosis & Treatment, Cardiology Services
Hospital Interzonal de Agudos “Eva Perón”
San Martin, Buenos Aires, Argentina


Felipe Martínez, MD, FACC, FECS
Professor of Medicine
Cordoba National University
Director of Rusculleda Foundation
Cordoba, Argentina

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Ricardo Alberto Migliore, MD – No disclosures
Felipe Martínez, MD, FACC, FECS – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 2

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 2

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
16 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Fonarow, 13:23 minutes: Expert discussion
Dr. Ventura, 2:50 minutes: Expert discussion

Presenters

Gregg Fonarow, MD, FACC, FAHA, FHFSA
Co-Chief of Cardiology
Director, Ahmanson-UCLA Preventative Cardiomyopathy Center
Ronald Reagan UCLA Medical Center
Los Angeles, CA


Hector Ventura, MD
Section Head, Cardiomyopathy and Heart Transplantation
Ochsner Medical Center
New Orleans, LA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Greg Fonarow, MD, FACC, FAHA, FHFSA – Novartis, Medtronic, Janssen, Bayer, ST. Jude, Amgen: Consultant/Advisory Board
Hector Ventura, MD – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
16 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Fonarow, 13:23 minutes: Expert discussion
Dr. Ventura, 2:50 minutes: Expert discussion

Presenters

Gregg Fonarow, MD, FACC, FAHA, FHFSA
Co-Chief of Cardiology
Director, Ahmanson-UCLA Preventative Cardiomyopathy Center
Ronald Reagan UCLA Medical Center
Los Angeles, CA


Hector Ventura, MD
Section Head, Cardiomyopathy and Heart Transplantation
Ochsner Medical Center
New Orleans, LA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Greg Fonarow, MD, FACC, FAHA, FHFSA – Novartis, Medtronic, Janssen, Bayer, ST. Jude, Amgen: Consultant/Advisory Board
Hector Ventura, MD – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages